Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Engineering an Artificial T-Cell Stimulating Matrix for Immunotherapy.

Hickey JW, Dong Y, Chung JW, Salathe SF, Pruitt HC, Li X, Chang C, Fraser AK, Bessell CA, Ewald AJ, Gerecht S, Mao HQ, Schneck JP.

Adv Mater. 2019 Jun;31(23):e1807359. doi: 10.1002/adma.201807359. Epub 2019 Apr 10.

PMID:
30968468
2.

Collagen fiber structure guides 3D motility of cytotoxic T lymphocytes.

Pruitt HC, Lewis D, Ciccaglione M, Connor S, Smith Q, Hickey JW, Schneck JP, Gerecht S.

Matrix Biol. 2019 Feb 16. pii: S0945-053X(18)30458-X. doi: 10.1016/j.matbio.2019.02.003. [Epub ahead of print]

PMID:
30776427
3.

High-affinity T cell receptors for adoptive cell transfer.

Isser A, Schneck JP.

J Clin Invest. 2019 Jan 2;129(1):69-71. doi: 10.1172/JCI125471. Epub 2018 Dec 10.

4.

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles.

Hickey JW, Schneck JP.

J Vis Exp. 2018 Nov 17;(141). doi: 10.3791/58640.

PMID:
30507913
5.

Efficient magnetic enrichment of antigen-specific T cells by engineering particle properties.

Hickey JW, Isser AY, Vicente FP, Warner SB, Mao HQ, Schneck JP.

Biomaterials. 2018 Dec;187:105-116. doi: 10.1016/j.biomaterials.2018.09.029. Epub 2018 Sep 28.

PMID:
30312851
6.

Engineering Platforms for T Cell Modulation.

Hickey JW, Kosmides AK, Schneck JP.

Int Rev Cell Mol Biol. 2018;341:277-362. doi: 10.1016/bs.ircmb.2018.06.003. Epub 2018 Jul 30. Review.

PMID:
30262034
7.

Correction: Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells.

Schütz C, Varela JC, Perica K, Haupt C, Oelke M, Schneck JP.

Oncotarget. 2018 Aug 17;9(64):32401. doi: 10.18632/oncotarget.26018. eCollection 2018 Aug 17.

8.

Soluble MHC class I complexes for targeted immunotherapy.

Schappert A, Schneck JP, Suarez L, Oelke M, Schütz C.

Life Sci. 2018 Sep 15;209:255-258. doi: 10.1016/j.lfs.2018.08.023. Epub 2018 Aug 10. Review.

PMID:
30102903
9.

Separating T Cell Targeting Components onto Magnetically Clustered Nanoparticles Boosts Activation.

Kosmides AK, Necochea K, Hickey JW, Schneck JP.

Nano Lett. 2018 Mar 14;18(3):1916-1924. doi: 10.1021/acs.nanolett.7b05284. Epub 2018 Feb 28.

PMID:
29488768
10.

ImmunoMap: A Bioinformatics Tool for T-cell Repertoire Analysis.

Sidhom JW, Bessell CA, Havel JJ, Kosmides A, Chan TA, Schneck JP.

Cancer Immunol Res. 2018 Feb;6(2):151-162. doi: 10.1158/2326-6066.CIR-17-0114. Epub 2017 Dec 20.

11.

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL Jr, Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris LGT, Sidhom JW, Schneck JP, Horak CE, Weinhold N, Chan TA.

Cell. 2017 Nov 2;171(4):934-949.e16. doi: 10.1016/j.cell.2017.09.028. Epub 2017 Oct 12.

12.

Biologically Inspired Design of Nanoparticle Artificial Antigen-Presenting Cells for Immunomodulation.

Hickey JW, Vicente FP, Howard GP, Mao HQ, Schneck JP.

Nano Lett. 2017 Nov 8;17(11):7045-7054. doi: 10.1021/acs.nanolett.7b03734. Epub 2017 Oct 10.

PMID:
28994285
13.

Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth.

Kosmides AK, Sidhom JW, Fraser A, Bessell CA, Schneck JP.

ACS Nano. 2017 Jun 27;11(6):5417-5429. doi: 10.1021/acsnano.6b08152. Epub 2017 Jun 7.

PMID:
28589725
14.

Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma.

Kosmides AK, Meyer RA, Hickey JW, Aje K, Cheung KN, Green JJ, Schneck JP.

Biomaterials. 2017 Feb;118:16-26. doi: 10.1016/j.biomaterials.2016.11.038. Epub 2016 Dec 2.

15.

Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells.

Schütz C, Varela JC, Perica K, Haupt C, Oelke M, Schneck JP.

Oncotarget. 2016 Oct 18;7(42):68503-68512. doi: 10.18632/oncotarget.11785. Erratum in: Oncotarget. 2018 Aug 17;9(64):32401.

16.

VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells.

Tiper IV, Temkin SM, Spiegel S, Goldblum SE, Giuntoli RL 2nd, Oelke M, Schneck JP, Webb TJ.

Clin Cancer Res. 2016 Aug 15;22(16):4249-58. doi: 10.1158/1078-0432.CCR-15-2518. Epub 2016 Apr 13.

17.

Cytotoxic polyfunctionality maturation of cytomegalovirus-pp65-specific CD4 + and CD8 + T-cell responses in older adults positively correlates with response size.

Chiu YL, Lin CH, Sung BY, Chuang YF, Schneck JP, Kern F, Pawelec G, Wang GC.

Sci Rep. 2016 Jan 18;6:19227. doi: 10.1038/srep19227.

18.

Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy.

Perica K, Bieler JG, Schütz C, Varela JC, Douglass J, Skora A, Chiu YL, Oelke M, Kinzler K, Zhou S, Vogelstein B, Schneck JP.

ACS Nano. 2015 Jul 28;9(7):6861-71. doi: 10.1021/acsnano.5b02829. Epub 2015 Jul 14.

19.

Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation.

Meyer RA, Sunshine JC, Perica K, Kosmides AK, Aje K, Schneck JP, Green JJ.

Small. 2015 Apr;11(13):1519-25. doi: 10.1002/smll.201402369. Epub 2015 Jan 12.

20.

CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells.

Bruns H, Bessell C, Varela JC, Haupt C, Fang J, Pasemann S, Mackensen A, Oelke M, Schneck JP, Schütz C.

Clin Cancer Res. 2015 May 1;21(9):2075-83. doi: 10.1158/1078-0432.CCR-14-2696. Epub 2015 Jan 15.

21.

MHC-Ig induces memory T cell formation in vivo and inhibits tumour growth.

Schütz C, Zoso A, Peng S, Bennett JD, Schneck JP, Oelke M.

Immun Inflamm Dis. 2014 Nov;2(3):181-92. doi: 10.1002/iid3.35. Epub 2014 Nov 11.

22.

Linking form to function: Biophysical aspects of artificial antigen presenting cell design.

Perica K, Kosmides AK, Schneck JP.

Biochim Biophys Acta. 2015 Apr;1853(4):781-90. doi: 10.1016/j.bbamcr.2014.09.001. Epub 2014 Sep 6. Review.

23.

Killer artificial antigen presenting cells (KaAPC) for efficient in vitro depletion of human antigen-specific T cells.

Schütz C, Fleck M, Schneck JP, Oelke M.

J Vis Exp. 2014 Aug 11;(90):e51859. doi: 10.3791/51859.

24.

Magnetic field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity.

Perica K, Tu A, Richter A, Bieler JG, Edidin M, Schneck JP.

ACS Nano. 2014 Mar 25;8(3):2252-60. doi: 10.1021/nn405520d. Epub 2014 Feb 24.

25.

Sprouty-2 regulates HIV-specific T cell polyfunctionality.

Chiu YL, Shan L, Huang H, Haupt C, Bessell C, Canaday DH, Zhang H, Ho YC, Powell JD, Oelke M, Margolick JB, Blankson JN, Griffin DE, Schneck JP.

J Clin Invest. 2014 Jan;124(1):198-208.

26.

Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells.

Sunshine JC, Perica K, Schneck JP, Green JJ.

Biomaterials. 2014 Jan;35(1):269-277. doi: 10.1016/j.biomaterials.2013.09.050. Epub 2013 Oct 5.

27.

T-cell memory responses elicited by yellow fever vaccine are targeted to overlapping epitopes containing multiple HLA-I and -II binding motifs.

de Melo AB, Nascimento EJ, Braga-Neto U, Dhalia R, Silva AM, Oelke M, Schneck JP, Sidney J, Sette A, Montenegro SM, Marques ET.

PLoS Negl Trop Dis. 2013;7(1):e1938. doi: 10.1371/journal.pntd.0001938. Epub 2013 Jan 31.

28.

Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer.

Webb TJ, Li X, Giuntoli RL 2nd, Lopez PH, Heuser C, Schnaar RL, Tsuji M, Kurts C, Oelke M, Schneck JP.

Cancer Res. 2012 Aug 1;72(15):3744-52. doi: 10.1158/0008-5472.CAN-11-2695. Epub 2012 May 30.

29.

Quantum dot fluorescence characterizes the nanoscale organization of T cell receptors for antigen.

Boyle S, Kolin DL, Bieler JG, Schneck JP, Wiseman PW, Edidin M.

Biophys J. 2011 Dec 7;101(11):L57-9. doi: 10.1016/j.bpj.2011.10.028.

30.

Decline of influenza-specific CD8+ T cell repertoire in healthy geriatric donors.

Lee JB, Oelke M, Ramachandra L, Canaday DH, Schneck JP.

Immun Ageing. 2011 Aug 16;8:6. doi: 10.1186/1742-4933-8-6.

31.

Inhibition of Fas ligand in NOD mice unmasks a protective role for IL-10 against insulitis development.

Xiao Z, Mohamood AS, Uddin S, Gutfreund R, Nakata C, Marshall A, Kimura H, Caturegli P, Womer KL, Huang Y, Jie C, Chakravarti S, Schneck JP, Yagita H, Hamad AR.

Am J Pathol. 2011 Aug;179(2):725-32. doi: 10.1016/j.ajpath.2011.04.016. Epub 2011 Jun 15.

32.

HLA-Ig based artificial antigen presenting cells for efficient ex vivo expansion of human CTL.

Chiu YL, Schneck JP, Oelke M.

J Vis Exp. 2011 Apr 11;(50). pii: 2801. doi: 10.3791/2801.

33.

High-throughput lectin microarray-based analysis of live cell surface glycosylation.

Li Y, Tao SC, Zhu H, Schneck JP.

Curr Protoc Protein Sci. 2011 Feb;Chapter 12:Unit12.9. doi: 10.1002/0471140864.ps1209s63.

34.

Novel cellular microarray assay for profiling T-cell peptide antigen specificities.

Yue C, Oelke M, Paulaitis ME, Schneck JP.

J Proteome Res. 2010 Nov 5;9(11):5629-37. doi: 10.1021/pr100447b. Epub 2010 Oct 4.

35.

Killer artificial antigen-presenting cells: the synthetic embodiment of a 'guided missile'.

Schütz C, Oelke M, Schneck JP, Mackensen A, Fleck M.

Immunotherapy. 2010 Jul;2(4):539-50. doi: 10.2217/imt.10.26. Review.

36.

Dynamic regulation of functionally distinct virus-specific T cells.

Ndhlovu ZM, Oelke M, Schneck JP, Griffin DE.

Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3669-74. doi: 10.1073/pnas.0915168107. Epub 2010 Feb 4.

37.

Overview of a HLA-Ig based "Lego-like system" for T cell monitoring, modulation and expansion.

Oelke M, Schneck JP.

Immunol Res. 2010 Jul;47(1-3):248-56. doi: 10.1007/s12026-009-8156-z. Review.

38.

In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.

Ugel S, Zoso A, De Santo C, Li Y, Marigo I, Zanovello P, Scarselli E, Cipriani B, Oelke M, Schneck JP, Bronte V.

Cancer Res. 2009 Dec 15;69(24):9376-84. doi: 10.1158/0008-5472.CAN-09-0400.

39.

Streptococcus pneumoniae serotype 1 capsular polysaccharide induces CD8CD28 regulatory T lymphocytes by TCR crosslinking.

Mertens J, Fabri M, Zingarelli A, Kubacki T, Meemboor S, Groneck L, Seeger J, Bessler M, Hafke H, Odenthal M, Bieler JG, Kalka C, Schneck JP, Kashkar H, Kalka-Moll WM.

PLoS Pathog. 2009 Sep;5(9):e1000596. doi: 10.1371/journal.ppat.1000596. Epub 2009 Sep 25.

40.

Development of an artificial-antigen-presenting-cell-based assay for the detection of low-frequency virus-specific CD8(+) T cells in whole blood, with application for measles virus.

Ndhlovu ZM, Angenendt M, Heckel D, Schneck JP, Griffin DE, Oelke M.

Clin Vaccine Immunol. 2009 Jul;16(7):1066-73. doi: 10.1128/CVI.00365-08. Epub 2009 Jun 3.

41.

Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells.

Webb TJ, Bieler JG, Schneck JP, Oelke M.

J Immunol Methods. 2009 Jul 31;346(1-2):38-44. doi: 10.1016/j.jim.2009.05.003. Epub 2009 May 14.

42.

Fas-mediated apoptosis regulates the composition of peripheral alphabeta T cell repertoire by constitutively purging out double negative T cells.

Mohamood AS, Bargatze D, Xiao Z, Jie C, Yagita H, Ruben D, Watson J, Chakravarti S, Schneck JP, Hamad AR.

PLoS One. 2008;3(10):e3465. doi: 10.1371/journal.pone.0003465. Epub 2008 Oct 21.

43.

Lectin microarrays identify cell-specific and functionally significant cell surface glycan markers.

Tao SC, Li Y, Zhou J, Qian J, Schnaar RL, Zhang Y, Goldstein IJ, Zhu H, Schneck JP.

Glycobiology. 2008 Oct;18(10):761-9. doi: 10.1093/glycob/cwn063. Epub 2008 Jul 14.

44.

In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC).

Durai M, Krueger C, Ye Z, Cheng L, Mackensen A, Oelke M, Schneck JP.

Cancer Immunol Immunother. 2009 Feb;58(2):209-20. doi: 10.1007/s00262-008-0542-1. Epub 2008 Jun 18.

45.

Monitoring antigen-specific T cells using MHC-Ig dimers.

Schneck JP, Slansky JE, O'Herrin SM, Greten TF.

Curr Protoc Immunol. 2001 May;Chapter 17:Unit 17.2. doi: 10.1002/0471142735.im1702s35.

PMID:
18432743
46.

Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells.

Schütz C, Fleck M, Mackensen A, Zoso A, Halbritter D, Schneck JP, Oelke M.

Blood. 2008 Apr 1;111(7):3546-52. Epub 2007 Dec 20.

47.

Protection from autoimmune diabetes and T-cell lymphoproliferation induced by FasL mutation are differentially regulated and can be uncoupled pharmacologically.

Mohamood AS, Guler ML, Xiao Z, Zheng D, Hess A, Wang Y, Yagita H, Schneck JP, Hamad AR.

Am J Pathol. 2007 Jul;171(1):97-106.

48.

A nanoscopic multivalent antigen-presenting carrier for sensitive detection and drug delivery to T cells.

Fahmy TM, Schneck JP, Saltzman WM.

Nanomedicine. 2007 Mar;3(1):75-85.

PMID:
17379171
49.

Detection of antigen-specific T cells on p/MHC microarrays.

Deviren G, Gupta K, Paulaitis ME, Schneck JP.

J Mol Recognit. 2007 Jan-Feb;20(1):32-8.

PMID:
17094178
50.

Gld mutation of Fas ligand increases the frequency and up-regulates cell survival genes in CD25+CD4+ TR cells.

Mohamood AS, Trujillo CJ, Zheng D, Jie C, Murillo FM, Schneck JP, Hamad AR.

Int Immunol. 2006 Aug;18(8):1265-77. Epub 2006 Jun 12.

PMID:
16769751

Supplemental Content

Loading ...
Support Center